TruePath™

Chronic Total Occlusion Device (CTO) Device

TruePath^TM CTO Device

No capital equipment

Diamond-coated distal tip rotating at 13,000 rpm

TruePath^TM CTO Device overview animation

Dr. James Park successfully crosses a 20cm CTO utilizing the TruePath^TMCTO Device, guidewires, and a support catheter.

Case Study - Dr. Mustapha

A powerful new solution for intraluminal treatment of chronic total occlusions. At 0.018”/0 .46 mm in diameter, the guidewire-like profile is nearly half the size of competitive offerings, designed for optimal steering and crossing. Once positioned, the self-rotating tip works effortlessly.

Request a Sales Rep

Sign-up for Product Updates

Submit Your Questions

Explore

Product Details

TruePath: A Powerful new solution for intraluminal treatment of chronic total occlusions.

Power

Diamond-coated distal tip rotating at 13,000 rpm

Profile

0.018”/0.46 mm guidewire-like profile, half the size of competitive offerings
Longest crossing device—165cm
Designed for optimal steering and crossing

Ease of use

No capital equipment
1:1 torque response
Audio and visual navigation aid in CTO navigation
Shapeable distal tip
Extension wire option, providing over 300 cm of working length for catheter exchange

TruePathᵀᴹ CTO-Device

Shaping Tool	Motor Housing	Control Unit

Ordering Information

TruePathᵀᴹ CTO-Device

TruePathᵀᴹ CTO-Device
UPN	Catalog No.	Description
H74939208181650	39208-18165	TruePath CTO Device
H74939208001601	39208-00160	TruePath Extension Wires (5/box)

TruePathᵀᴹ Compatibility
Size (OD)	Length	Sheath Compatibility	Min. Guide Catheter ID	Tip Profile
0.018" / 0.46 mm	165 cm	≥ 0.018" / 0.46 mm compatible Catheters¹	≥ 0.018" / 0.46 mm	0.017" / 0.43 mm

Clinical Information

ReOpen Study Objective

Demonstrate that TruePath CTO Device is safe and effective to facilitate crossing infrainguinal artery CTOs following resistance to crossing with a conventional guidewire or a prior failed attempt.
- 85 Subjects
- 3 centers in Europe

Key Clinical Results
	All Patients: (n=85)
Safety Endpoint
Freedom from clinical perforation (any perforation requiring treatment) of the index lesion to 30 days	98.8% (*84/85)

Technical Success
Facilitation of crossing the CTO with the TruePath CTO Device and/or any guidewire	80.0% (68/85)